SHANGHAI, November 24 /PRNewswire/ -- NOD Pharmaceuticals Inc. announced the US Patent Trademark Office (PTO) has allowed the patent application for its nano-particle oral delivery or NOD technology.

NOD technology is a highly efficient approach to incorporate peptides or proteins into bio-adhesive nano-particles to enable oral delivery of drugs otherwise administered as injections. NOD technology is a platform technology that can be applied to many macromolecular drugs such as insulin, interferon, growth hormone, exenatide, heparin and more.

Currently, an oral insulin formulation, the first candidate developed with NOD technology, is entering phase I clinical studies in China.

Patent allowance for NOD technology is a major step forward for NOD, quoted from William Lee, CEO. With this patent, and in combination with others, NOD is building a solid foundation for its intellectual property and core competence.

For more information, please contact: William Lee, Ph.D., CEO Phone: +86-21-6194-0758 Email: info@nodpharm.com

Notes for Editors

About NOD Pharmaceuticals

NOD Pharmaceuticals, Inc. is a development stage biotech company and emerging leader in innovative delivery for biopharmaceuticals. NOD uses patented platform technology, nano-particle oral delivery or NOD technology, to develop oral formulations for biopharmaceuticals, including insulin, exenatide, interferon, human growth hormone and more.

More information can be found at http://www.nodpharm.com .

SOURCE: NOD Pharmaceuticals, Inc.

CONTACT: William Lee, Ph.D., CEO, +86-21-6194-0758, or info@biolaxy.com